Literature DB >> 14522300

Reproducibility of morphoscopic contrast sensitivity testing with the Visual Capacity Analyzer.

Hyung Kuen Lee1, Il Hwan Koh, Chul Myong Choe, Chan Yoon Kim, Young Jae Hong, Gong Je Seong.   

Abstract

PURPOSE: To determine the reproducibility of morphoscopic contrast sensitivity test values in healthy subjects using the Visual Capacity Analyzer (VCA) (L2 Informatique).
SETTING: Institute of Vision Research, Department of Ophthalmology, Yong-Dong Severance Hospital, Yonsei University, Seoul, South Korea.
METHODS: Five healthy volunteers were recruited for this study. With the VCA, 1 eye of each person was tested with different sized letters displayed on a computer screen at 11 spatial frequencies ranging from low (3.0 cycles/deg [cpd]) to high (30.0 cpd). The measurement was repeated 5 times under 2 screen luminance levels (maximum and 3 cd/m2).
RESULTS: Under maximum luminance background, the coefficient of variation (CV) and reliability coefficient (RC) at the spatial frequencies examined ranged from 4.3% to 35.0% and 89.1% to 99.8%, respectively. Under a screen luminance of 3 cd/m2, the CV ranged from 0.5% to 15.9% and the RC, from 97.5% to 100.0%.
CONCLUSION: At the spatial frequencies examined, morphoscopic contrast sensitivity testing using the VCA had a high level of reproducibility and may be useful in measuring a patient's visual function in the actual environment.

Entities:  

Mesh:

Year:  2003        PMID: 14522300     DOI: 10.1016/s0886-3350(03)00044-0

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

1.  Visual quality after wavefront-guided LASIK for myopia.

Authors:  Hyojin Kim; Choun-Ki Joo
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

2.  Evaluation of the precision of contrast sensitivity function assessment on a tablet device.

Authors:  Michael Dorr; Luis A Lesmes; Tobias Elze; Hui Wang; Zhong-Lin Lu; Peter J Bex
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.